Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients

Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a significant contributor to the global cancer burden. lutetium-177-prostate-specific membrane antigen radioligand therapy (<sup>177</sup>Lu-PSMA RLT) is an effective salvage treatment. However, studies have high...

Full description

Bibliographic Details
Main Authors: Murali Kesavan, Danielle Meyrick, Marat Gallyamov, J. Harvey Turner, Sharon Yeo, Giuseppe Cardaci, Nat P. Lenzo
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Diagnostics
Subjects:
LuPSMA
mCRPC
hematologic toxicity
MDS
Online Access:https://www.mdpi.com/2075-4418/11/3/515

Internet

https://www.mdpi.com/2075-4418/11/3/515

Similar Items